690 related articles for article (PubMed ID: 32216826)
21. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
22. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.
Lal A; Chan L; Devries S; Chin K; Scott GK; Benz CC; Chen YY; Waldman FM; Hwang ES
Breast Cancer Res Treat; 2013 Jun; 139(2):381-90. PubMed ID: 23712790
[TBL] [Abstract][Full Text] [Related]
23. Associations of B7-H3 and B7-H4 Expression in Ductal Carcinoma In Situ of the Breast With Clinicopathologic Features and T-Cell Infiltration.
Kim NI; Park MH; Lee JS
Appl Immunohistochem Mol Morphol; 2020; 28(10):767-775. PubMed ID: 31714284
[TBL] [Abstract][Full Text] [Related]
24. The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.
Ubago JM; Blanco LZ; Shen T; Siziopikou KP
Am J Clin Pathol; 2019 Jul; 152(2):169-176. PubMed ID: 30984969
[TBL] [Abstract][Full Text] [Related]
25. Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent.
Agahozo MC; Westenend PJ; van Bockstal MR; Hansum T; Giang J; Matlung SE; van Deurzen CHM
Mod Pathol; 2020 Sep; 33(9):1773-1782. PubMed ID: 32341499
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.
Thompson ED; Taube JM; Asch-Kendrick RJ; Ogurtsova A; Xu H; Sharma R; Meeker A; Argani P; Emens LA; Cimino-Mathews A
Mod Pathol; 2017 Nov; 30(11):1551-1560. PubMed ID: 28731046
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
28. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
[TBL] [Abstract][Full Text] [Related]
30. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
Eich ML; Chaux A; Guner G; Taheri D; Mendoza Rodriguez MA; Rodriguez Peña MDC; Baras AS; Hahn NM; Drake C; Sharma R; Bivalacqua TJ; Rezaei K; Netto GJ
Hum Pathol; 2019 Jul; 89():24-32. PubMed ID: 31026471
[TBL] [Abstract][Full Text] [Related]
31. An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes.
Kim A; Heo SH; Kim YA; Gong G; Jin Lee H
Am J Clin Pathol; 2016 Jul; 146(1):137-44. PubMed ID: 27402610
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
Hu C; Tian S; Lin L; Zhang J; Ding H
Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
[TBL] [Abstract][Full Text] [Related]
34. Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).
Darvishian F; Ozerdem U; Adams S; Chun J; Pirraglia E; Kaplowitz E; Guth A; Axelrod D; Shapiro R; Price A; Troxel A; Schnabel F; Roses D
Ann Surg Oncol; 2019 Oct; 26(10):3337-3343. PubMed ID: 31240590
[TBL] [Abstract][Full Text] [Related]
35. Immune parameters associated with survival in metaplastic breast cancer.
Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.
Almekinders MM; Bismeijer T; Kumar T; Yang F; Thijssen B; van der Linden R; van Rooijen C; Vonk S; Sun B; Parra Cuentas ER; Wistuba II; Krishnamurthy S; Visser LL; Seignette IM; Hofland I; Sanders J; Broeks A; Love JK; Menegaz B; Wessels L; Thompson AM; de Visser KE; Hooijberg E; Lips E; Futreal A; Wesseling J;
Br J Cancer; 2022 Oct; 127(7):1201-1213. PubMed ID: 35768550
[TBL] [Abstract][Full Text] [Related]
37. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
[TBL] [Abstract][Full Text] [Related]
38. The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor.
Won KY; Kim GY; Kim HK; Song MJ; Choi SI; Bae GE; Lim SJ
Pathol Res Pract; 2019 Nov; 215(11):152639. PubMed ID: 31582185
[TBL] [Abstract][Full Text] [Related]
39. Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathological parameters.
Zeng L; Koh VCY; Chen XY; Tan PH
Histopathology; 2023 Apr; 82(5):779-788. PubMed ID: 36635954
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
